Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385931 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
A Phase 3 study of Hypertension and Hypercholesterolemia, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 412
- Enrollment target
- 1
- Study location
NCT00385931: Completed Phase 3 study of Hypertension and Hypercholesterolemia, sponsored by Novartis.
NCT00385931 is a Phase 3 study of Hypertension and Hypercholesterolemia that has completed, run by Novartis. The registered enrollment target is 412 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00385931, a Phase 3 study of Hypertension and Hypercholesterolemia, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 412 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess and compare the efficacy and safety of valsartan and the combination of valsartan and simvastatin in patients with high blood pressure and high cholesterol.
Conditions Studied
Interventions
- DRUG Valsartan and simvastatin
Study Locations (1)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2002-01 |
| Est. Completion | 2003-04 |
| Phase | Phase 3 |
What the finished NCT00385931 record still lists
NCT00385931 is an interventional study that assigns participants to a tested intervention. The registered 412 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Valsartan and simvastatin is the first listed.
NCT00385931 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00385931 about?
NCT00385931 is a clinical study titled "Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin". This study will assess and compare the efficacy and safety of valsartan and the combination of valsartan and simvastatin in patients with high blood pressure and high cholesterol.
What is the current status of trial NCT00385931?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 412 participants. The study started on 2002-01. Estimated completion is 2003-04.
What conditions does trial NCT00385931 study?
This clinical trial studies the following conditions: Hypertension, Hypercholesterolemia, Dyslipidemia.
What interventions are being tested in trial NCT00385931?
The interventions under investigation include: Valsartan and simvastatin (DRUG).
Who is sponsoring clinical trial NCT00385931?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00385931 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00385931's enrollment target sits among peer trials
412 144th of 470 higher than 327 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia